3-(氯甲基)-5-(2-氟苯基)-1,2,4-恶二唑 | 844499-00-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 3-(氯甲基)-5-(2-氟苯基)-1,2,4-恶二唑
• 中文别名: 3-(氯甲基)-5-(2-氟苯基)-1,2,4-噁二唑
• 英文名称: 3-(Chloromethyl)-5-(2-fluorophenyl)-1,2,4-oxadiazole
• CAS: 844499-00-9
• 化学式: C₉H₆ClFN₂O
• mdl: MFCD09027636
• 分子量: 212.611
• InChiKey: ZIPXONDQMIHZSE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  38.9
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  3-(氯甲基)-5-(2-氟苯基)-1,2,4-恶二唑 在 盐酸 、 potassium carbonate 作用下， 以 乙醇 、 丙酮 为溶剂， 生成 8-(4-{[5-(2-fluorophenyl)(1,2,4-oxadiazol-3-yl)]methoxy}phenyl)-1,3-dipropyl-1,3,7-trihydropurine-2,6-dione
  参考文献：
  名称：

  The discovery of a selective, high affinity A2B adenosine receptor antagonist for the potential treatment of asthma

  摘要：

  Adenosine has been suggested to play a role in asthma, possibly via activation of A(2B) adenosine receptors on mast cells and other pulmonary cells. We describe our initial efforts to discover a xanthine based selective A(2B) AdoR antagonist that resulted in the discovery of CVT-5440, a high affinity A(2B) AdoR antagonist with good selectivity (A(2B) AdoR K-i = 50 nM, selectivity A(1) > 200: A(2A) > 200: A(3) > 167). (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.11.044
• 作为产物：
  描述：

  邻氟苯甲酰氯 在 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 反应 48.0h， 生成 3-(氯甲基)-5-(2-氟苯基)-1,2,4-恶二唑
  参考文献：
  名称：

  The discovery of a selective, high affinity A2B adenosine receptor antagonist for the potential treatment of asthma

  摘要：

  Adenosine has been suggested to play a role in asthma, possibly via activation of A(2B) adenosine receptors on mast cells and other pulmonary cells. We describe our initial efforts to discover a xanthine based selective A(2B) AdoR antagonist that resulted in the discovery of CVT-5440, a high affinity A(2B) AdoR antagonist with good selectivity (A(2B) AdoR K-i = 50 nM, selectivity A(1) > 200: A(2A) > 200: A(3) > 167). (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.11.044

文献信息

• [EN] ALKALOID AMINOESTER DERIVATIVES AND MEDICINAL COMPOSITION THEREOF<br/>[FR] DÉRIVÉS AMINOESTER D'ALKALOÏDES ET COMPOSITION MÉDICINALE LES COMPRENANT
  申请人：CHIESI FARMA SPA

  公开号：WO2011160919A1

  公开（公告）日：2011-12-29

  The present invention relates to alkaloid aminoester derivatives acting as muscarinic receptor antagonists, processes for their preparation, compositions comprising them and therapeutic uses thereof.

  本发明涉及作为毒蕈碱受体拮抗剂的生物碱氨基酸酯衍生物，它们的制备方法，包含它们的组合物及其治疗用途。
• ALKALOID AMINOESTER DERIVATIVES AND MEDICINAL COMPOSITION THEREOF
  申请人：AMARI Gabriele

  公开号：US20110311459A1

  公开（公告）日：2011-12-22

  The present invention relates to alkaloid aminoester compounds which act as muscarinic receptor antagonists, processes for the preparation of such a compound, compositions which contain such a compound, and therapeutic uses of such a compound.

  本发明涉及作为毒蕈碱受体拮抗剂的生物碱氨基酯化合物，制备此类化合物的方法，含有此类化合物的组合物，以及此类化合物的治疗用途。
• New GABA-modulating 1,2,4-oxadiazole derivatives and their anticonvulsant activity
  作者：Hans-Joachim Lankau、Klaus Unverferth、Christian Grunwald、Helge Hartenhauer、Kristina Heinecke、Katrin Bernöster、Rita Dost、Ute Egerland、Chris Rundfeldt

  DOI：10.1016/j.ejmech.2006.12.022

  日期：2007.6

  A series of 3- and 5-aryl-1,2,4-oxadiazole derivatives were prepared and tested for anticonvulsant activity in a variety of models. These 1,2,4oxadiazoles exhibit considerable activity in both pentylenetetrazole (PTZ) and maximal electroshock seizure (MES) models. Compound 10 was protective in the PTZ model in rats with an oral ED50 of 25.5 mg/kg and in the MES model in rats with an oral ED50 Of 14.6 mg/kg. Neurotoxicity (rotarod) was observed with an ED50 Of 335 mg/kg. We found several oxadiazoles that acted as selective GABA potentiating compounds with no interaction to the benzodiazepine binding site. (c) 2007 Elsevier Masson SAS. All rights reserved.
• Alkaloid aminoester derivatives and medicinal compositions thereof
  申请人：Chiesi Farmaceutici S.p.A.

  公开号：EP2585458B1

  公开（公告）日：2015-01-07
• US8563577B2
  申请人：——

  公开号：US8563577B2

  公开（公告）日：2013-10-22